6:35 PM
 | 
Jan 18, 2008
 |  BC Extra  |  Company News

GSK passes on Exelixis' XL784

Exelixis (NASDAQ:EXEL) said GlaxoSmithKline (LSE:GSK; NYSE:GSK) decided not to exercise its option to license XL784 under a 2002 deal to discover and develop small molecules to treat cancer and vascular and inflammatory...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >